Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Updates on the FLT3 inhibitor FF-10101 for the treatment of R/R AML

Mark Levis • 4 Sep 2024
SOHO 2024
Acute Myeloid Leukemia Leukemia FF-10101-01 Gilteritinib Midostaurin Quizartinib

Mark Levis, MD, PhD, John Hopkins University, Baltimore, MD, highlights the benefits of the irreversible FLT3 inhibitor FF-10101 for the treatment of refractory/relapsed acute myeloid leukemia (R/R AML), including its short half-life and dosage. Dr Levis expresses disappointment over its halt in development but mentions a similar drug that has demonstrated promising potential. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Mark Levis

Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3m AML
0:46
Updates on the QuANTUM-First trial: quizartinib plus chemotherapy in newly diagnosed FLT3m AML
Mark Levis • 12 Jun 2026
The impact of prior induction cycle number on outcomes with gilteritinib in R/R FLT3-mutated AML
0:53
The impact of prior induction cycle number on outcomes with gilteritinib in R/R FLT3-mutated AML
Mark Levis • 12 Jun 2026
Datasets at ASH 2025 that will refine the management of FLT3-mutated AML
1:39
Datasets at ASH 2025 that will refine the management of FLT3-mutated AML
Mark Levis • 5 Dec 2025
Understanding the results of MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD AML
2:03
Understanding the results of MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD AML
Mark Levis • 5 Dec 2025

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals